Managing the anemia of prematurity: red blood cell transfusions versus recombinant erythropoietin

Transfus Med Rev. 2001 Jul;15(3):213-23. doi: 10.1053/tmrv.2001.24592.

Abstract

Transfusion-dependent anemia remains a problem for preterm infants, particularly those with a birth weight less than 1.0 kg. Several studies have documented the efficacy and safety of transfusing red blood cells stored up to 42 days as a means to diminish donor exposures. Recombinant erythropoietin therapy has not been widely adopted because it does not consistently reduce the need for red blood cell transfusions in very low-birth weight preterm infants.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Anemia, Neonatal / blood
  • Anemia, Neonatal / complications
  • Anemia, Neonatal / therapy*
  • Erythrocyte Transfusion / methods
  • Erythropoietin / therapeutic use
  • Hematocrit
  • Humans
  • Infant, Newborn
  • Infant, Premature, Diseases / blood
  • Infant, Premature, Diseases / therapy*
  • Recombinant Proteins

Substances

  • Recombinant Proteins
  • Erythropoietin